Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services that include human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carrier with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.
Metrics to compare | 6615 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6615PeersSector | |
|---|---|---|---|---|
P/E Ratio | −73.8x | −0.9x | −0.6x | |
PEG Ratio | 0.50 | −1.82 | 0.00 | |
Price/Book | 1.2x | −62.4x | 2.6x | |
Price / LTM Sales | 1.9x | 7.9x | 3.3x | |
Upside (Analyst Target) | - | 40.4% | 44.5% | |
Fair Value Upside | Unlock | 5.4% | 5.0% | Unlock |